glp-1 drugs pharmaceutical companies news 2025 Receptor Agonist Market Valued at USD 62.86 Billion in 2025, Set to Grow at 17.5% CAGR Through 2034 How Supply and Demand for

A novel polysaccharide-based approach from macromolecular interactions: control of postharvest Botrytis cinerea by mannoprotein and sodium alginate

SGLT2 inhibitors cause your kidneys to release more glucose into your urine and remove it from your body, which can lead to calorie loss

I think AI is going to lead to a rise in people wanting more control and autonomy over their bodies, because there is a rising dissatisfaction or dissonance with medical science after Covid-19

(CALC), announced the discontinuation of its Phase 2 KOURAGE clinical trial that evaluates Auxora in patients with Stage 2 or Stage 3 acute kidney injury with associated acute hypoxemic respiratory failure, following a recommendation from the Independent Data Monitoring Committee